Cue Biopharma, Inc.
General ticker "CUE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $44.2M (TTM average)
Cue Biopharma, Inc. follows the US Stock Market performance with the rate: 42.1%.
Estimated limits based on current volatility of 6.7%: low 25.61$, high 29.29$
Factors to consider:
- Total employees count: 41 (-22.6%) as of 2024
- Top business risk factors: Insufficient capital, Regulatory and compliance, Clinical trial delays, IP protection failure, Labor/talent shortage/retention
- Current price 51.8% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.85$, 17.77$]
- 2026-12-31 to 2027-12-31 estimated range: [4.24$, 13.04$]
Financial Metrics affecting the CUE estimates:
- Negative: with PPE of -0.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -82.29 <= 0.28
- Positive: 42.26 < Shareholder equity ratio, % of 62.62 <= 63.63
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0.28 > -0.64
Short-term CUE quotes
Long-term CUE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $5.33MM | $9.38MM | $27.43MM |
| Operating Expenses | $57.48MM | $50.88MM | $53.99MM |
| Operating Income | $-52.15MM | $-41.50MM | $-26.55MM |
| Non-Operating Income | $1.42MM | $0.83MM | $0.45MM |
| R&D Expense | $40.80MM | $36.30MM | $37.74MM |
| Income(Loss) | $-50.73MM | $-40.67MM | $-26.10MM |
| Taxes | $0.00MM | $0.00MM | $0.50MM |
| Net Income(Loss)* | $-50.73MM | $-40.67MM | $-26.60MM |
| Stockholders Equity | $37.09MM | $17.50MM | $26.43MM |
| Assets | $61.53MM | $32.19MM | $42.21MM |
| Operating Cash Flow | $-39.96MM | $-36.33MM | $-21.69MM |
| Capital expenditure | $0.00MM | $0.07MM | $0.18MM |
| Investing Cash Flow | $25.00MM | $0.03MM | $0.07MM |
| Financing Cash Flow | $11.86MM | $10.24MM | $26.29MM |
| Earnings Per Share** | $-33.26 | $-21.66 | $-8.42 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.